Sowers and colleagues conducted a double-blind, randomized trial to evaluate the effects of celecoxib, rofecoxib, and naproxen on 24-hour systolic blood pressure (SBP) in 404 treated hypertensive patients with osteoarthritis and type 2 diabetes mellitus. Reductions in osteoarthritis symptoms, including pain, mobility, and stiffness, were similar in all treatment groups. Increases in 24-hour SBP occurred for rofecoxib compared with celecoxib (3.78 mm Hg; 95% confidence interval, 1.18-6.38 mm Hg; P = .005) and for rofecoxib compared with naproxen (3.85 mm Hg; 95% confidence interval, 1.15-6.55 mm Hg; P = .005). These effects were primarily related to changes in the daytime SBP. Thus, at equally efficacious doses for osteoarthritis management, treatment with rofecoxib is more likely than celecoxib and naproxen to induce a significant increase in 24-hour SBP in patients with type 2 diabetes mellitus receiving antihypertensive therapies.